1. 352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial. (25th January 2023) Authors: Li, Hang; Cheng, Hao; Lu, Qianjin; Lai, Wei; Tao, Xiaohua; Encinas, Gerardo A; Vyas, Shefali; Wang, Bo; Luo, Xin; Li, Shiqi Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗